Bioenvision Report issue

Contributed to NME For profit Phase 2
Founded: New York NY United States (1996)
Status: Acquired by Genzyme (2007) → now Sanofi-Aventis (2011)

Organization Overview

First Clinical Trial
2003
NCT00930098
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOENVISION | Bioenvision, Inc

Active Ingredients

Marketed Drugs (1)

trilostane (modrastane) (1984)

Drugs in Phase 2 Trials (1)

clofarabine (clolar) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1